
Nielsoft Refiled DRHP With SEBI For IPO: Check Key Insights
Updated: 2 Jun 2025 • 5:13 pm
Posted by:

Nielsoft Limited has filed its DRHP (Draft Red Herring Prospectus) with the Securities and Exchange Board of India (SEBI) for its upcoming IPO. It will be the book-building issue comprising a fresh issue and the offer for sale of equity shares. Scroll down to explore more about the key highlights of Nielsoft IPO.
Nielsoft IPO: Key Highlights
- Nielsoft IPO will be conducted under the supervision of its registrar- Link Intime India Private Limited, and its book-running lead managers- Equirus Capital Private Limited and IIFL Capital Services Limited.
- Nielsoft IPO will combine a fresh issue of the shares having a face value of ₹5 each, aggregating up to ₹100 crore and offer for sale of up to 80 lakh shares.
- As per the DRHP, shares of Nielsoft Limited will be listed on the NSE and BSE. However, the price band and minimum lot size are yet to be determined by the company.
About Nielsoft Limited
Nielsoft Limited was incorporated in 1991 and is an engineering firm in the research and development space. It serves its customers with specialised services in digitalisation and automation. Nielsoft Limited is backed by Fujita Corporation, a Japanese construction giant and has its footprint in India, Europe, the USA, and other Asia-Pacific regions.
Nielsoft Limited focuses on sectors such as architecture, manufacturing, industrial plants, engineering, and construction. It runs delivery centres in Pune, Ahmedabad, Bengaluru, Germany, and Tokyo. Nielsoft’s sales operations are extended across India, Canada, and the United Kingdom.
Nielsoft Limited Financials
Nielsoft Limited has shown a consistent growth in its financial performance for the FY24. The revenue from operations of Nielsoft Limited increased 11.96% YoY to reach at ₹325.85 crore against the previous year’s revenue of ₹291.03 crore. Moreover, the profit after tax also surged 24.05% to ₹57.85 crore over the same period.
Objectives of IPO
With this initial public offering (IPO), Nielsoft Limited aims to utilise these funds in different prospects.
- Purchase of software subscriptions and licenses.
- General corporate purposes.
- Civil construction and interior development at Viman Nagar Office.
- Purchase of a new computer graphics workstation and server storage.
Let’s Wrap
Nielsoft Limited refiled its DRHP with SEBI for its upcoming IPO. The Nielsoft shares are expected to be listed on the NSE and the BSE. The company aims to purchase software subscriptions, licenses, new computer graphics, server storage, etc, with the IPO proceeds.
For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Nykaa Q4 Results 2025: Q4 PAT Jumps 193%; Revenue Jumps 23%; Know More!!
Stock Market Today: Sensex Plunged 344 Points & Nifty50 By 0.42%; Check Key Insights
Stocks to Watch Today: 2nd June 2025 | Ajmera Realty, TCI Express, VI, Siti, Havels, & More!
Best Telecom Stocks in India in 2025: Telecom Sector Companies
Cummins India Q4 Results 2025: Profits Decline 7% to ₹521 crores; ₹33.50 per Share Dividend Declared
Samvardhana Motherson Q4 Results 2025: Q4 Net Profit Dips 22.75% YoY; Bonus Shares Declared
3B Films IPO GMP: Day 1 IPO Live Updates
Suzlon Energy Q4 Results 2025: Q4 Net Profits Skyrockets 365%; Revenue Surges 73%
IRCTC Q4 Results 2025: Q4 PAT Soars 26% to ₹358 crores; ₹1 Per Share Dividend Declared
Recent Articles
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Recent Posts
Transrail Lighting Analyst Review May 2026
Devyani International Q4 FY26 Results: Loss Rs 9.84 Cr, Revenue Rs 1,436.86 Crore
HBL Engineering Analyst Review May 2026
Gland Pharma Q4 FY26 Results: PAT Rs 367 Cr, Revenue Rs 1,743 Crore
Tata Chemicals Analyst Review May 2026
Popular this week
Transrail Lighting Analyst Review May 2026
Devyani International Q4 FY26 Results: Loss Rs 9.84 Cr, Revenue Rs 1,436.86 Crore
HBL Engineering Analyst Review May 2026
Gland Pharma Q4 FY26 Results: PAT Rs 367 Cr, Revenue Rs 1,743 Crore
Tata Chemicals Analyst Review May 2026

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
